glycerol has been researched along with Neoplasms in 120 studies
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously." | 5.39 | Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. ( Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013) |
| "Most neoplasms are dependent on glucose as their primary fuel, and their ambient glucose levels tend to be rather low owing to wasteful aerobic glycolysis and poor perfusion." | 5.31 | Prospects for glycerol-rescued hypoglycemia as a cancer therapy. ( McCarty, MF, 2001) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "A metabolic defect has been observed in extracts of lipomata in which citrate fails to inhibit the conversion of glucose-6-phosphate to glyceride-glycerol." | 3.65 | Regulatory defect of glycolysis in human lipoma. ( Atkinson, JN; Galton, DJ; Gilbert, C, 1974) |
| " The corresponding median values for the apparent bioavailability of oral Genetaxyl were similar when compared with i." | 2.73 | Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ( Chen, JS; Chen, PM; Chu, Z; Figg, WD; Gardner, ER; Liau, CT; Lin, YC; Sparreboom, A; Wang, HM; Yang, MH, 2008) |
| "Twenty-seven adults with cancer pain were prospectively selected according to their primary lesions and problems, but their allocation to study groups was randomized." | 2.67 | Prolongation of epidural bupivacaine analgesia with glycerin. ( King, H; Wooten, DJ; Xiao, CS, 1993) |
| " However, the use of paclitaxel is seriously limited (its bioavailability is <10%) due to several long-standing challenges: its poor water solubility (0." | 2.61 | Basic principles of drug delivery systems - the case of paclitaxel. ( Aserin, A; Ezrahi, S; Garti, N, 2019) |
| "In addition to effective cancer therapies like chemotherapy, radiotherapy and surgery, treatment based on traditional Chinese medicine (TCM) and combined TCM with western medicine has gradually gained attention in Oriental countries." | 2.61 | Potential of Fatty Oils from Traditional Chinese Medicine in Cancer Therapy: A Review for Phytochemical, Pharmacological and Clinical Studies. ( Feng, Y; Hong, Y; Huang, Y; Lin, X; Shen, L; Zhu, J, 2019) |
| "The taxanes' interaction with other anticancer drugs have been extensively investigated in in vitro and in animal models as well as in humans due to the outstanding antitumor activity in a broad range of malignancies." | 2.41 | Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. ( Gianni, L; Grasselli, G; Locatelli, A; Vigano, L, 2001) |
| "A mouse model of cancer cachexia was established where cancer exosomes were injected intravenously." | 1.91 | Breast cancer cell-derived exosome-delivered microRNA-155 targets UBQLN1 in adipocytes and facilitates cancer cachexia-related fat loss. ( Li, C; Li, Z; Sun, K; Sun, S; Wang, Z; Yao, F, 2023) |
| "The existence of cancer stem cells (CSCs) poses a major obstacle for the success of current cancer therapies, especially the fact that non-CSCs can spontaneously turn into CSCs, which lead to the failure of the treatment and tumor relapse." | 1.62 | Retinoic Acid-Loaded Dendritic Polyglycerol-Conjugated Gold Nanostars for Targeted Photothermal Therapy in Breast Cancer Stem Cells. ( Haag, R; Li, W; Liu, C; Ma, X; Pan, Y; Parshad, B; Schwerdtle, T; Wu, A; Xing, J; Zhou, S, 2021) |
| "For the combined therapy to breast cancer MCF-7 tumor, the co-delivery system of PCL-HPG-PEI600/DOX/pMMP-9 resulted in a much better inhibition effect on MCF-7 cell proliferation and migration in vitro as well as the suppression effect on MCF-7 tumors in vivo compared to those of single DOX or pMMP-9 formulation used." | 1.48 | Construction of a High-Efficiency Drug and Gene Co-Delivery System for Cancer Therapy from a pH-Sensitive Supramolecular Inclusion between Oligoethylenimine- graft-β-cyclodextrin and Hyperbranched Polyglycerol Derivative. ( Kirk, TB; Ma, D; Wu, J; Xu, J; Xu, L; Xue, W; Zhou, X, 2018) |
| "Subsequently, the anticancer agent doxorubicin (DOX) was loaded through acid-labile hydrazone linkage to yield dND-PG-DOX and dND-PG-RGD-DOX." | 1.40 | Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells. ( Abe, S; Akasaka, T; Chen, X; Komatsu, N; Watari, F; Xu, YH; Zhao, L, 2014) |
| "Since agAQPs are involved in cancer proliferation and malignancy, it might be possible to utilize them as new targets for cancer molecular imaging." | 1.39 | Molecular imaging of aquaglycero-aquaporins: its potential for cancer characterization. ( Furukawa, T; Obata, T; Saga, T; Saito, Y, 2013) |
| " PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously." | 1.39 | Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. ( Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013) |
| "The dose-dependent targeting and anticancer effect of the MNP-g-HPG-MTX nanoparticles were evaluated, and the results showed that depending on the amount of conjugated MTX and the concentration of the incubated nanoparticles, the uptake of MNP-g-HPG-MTX nanoparticles by human head and neck cancer (KB) cells can be eight times or more higher than those by 3T3 fibroblasts and RAW macrophages." | 1.39 | Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe₃O₄ magnetic nanoparticles for targeted anticancer effects. ( Kang, ET; Li, M; Neoh, KG; Tan, JY; Wang, R; Zong, BY, 2013) |
| "Xenograft studies of breast cancer revealed that the anti-tumor efficacy of PTX-NSP was equal to that of PTX-CrEL-D in tumors originating from both MDA-MB-435 and ZR-75-1 cancer lines." | 1.38 | Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. ( Bushman, J; Garbuzenko, OB; Gounder, MK; Kohn, J; Minko, T; Sheihet, L, 2012) |
| "Paclitaxel is a potent anti-cancer drug that has exhibited clinical activity against several tumours." | 1.38 | Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion. ( Chen, X; Liu, X; Scott, H; Sun, J; Wang, S; Zhang, Q; Zhang, X, 2012) |
| "In recent years, the number of cancer patients and their families desiring palliative home-based care in Japan has increased." | 1.38 | [Usefulness of subarachnoid phenol-glycerin block therapy for enabling cancer patients with refractory anal pain to proceed to home-based care]. ( Hayashi, S; Inoue, D; Kawakubo, T; Moriya, K; Sakuyama, T; Tanifuji, Y, 2012) |
| "Cachexia is a multifactorial wasting syndrome most common in patients with cancer that is characterized by the uncontrolled loss of adipose and muscle mass." | 1.37 | Adipose triglyceride lipase contributes to cancer-associated cachexia. ( Das, SK; Diwoky, C; Eder, S; Gorkiewicz, G; Guertl, B; Haemmerle, G; Hoefler, G; Kumari, P; Schauer, S; Tamilarasan, KP; Temmel, H; Trauner, M; Vesely, P; Zechner, R; Zimmermann, R, 2011) |
| "The 3PNET has been applied to two anticancer drugs, paclitaxel (PTX) and camptothecin (CPT), using Pluronic F127 (F127) polymer as a single excipient." | 1.36 | Targeted cancer therapy with novel high drug-loading nanocrystals. ( Bathula, SR; Conwell, C; Huang, L; Liu, F; Liu, Y; Park, JY; Zhang, Y, 2010) |
| " Benchmark dose analysis of the dose-response data for renal tubular hyperplasia in male and female rats exposed to 3-MCPD in drinking water for 2 years was conducted." | 1.35 | Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology. ( Hwang, M; Jang, DD; Kim, J; Yoo, TM; Yoon, E, 2009) |
| "The purpose of this study was to develop a population pharmacokinetic model for Cremophor EL used as a formulation vehicle for paclitaxel." | 1.31 | A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. ( Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O, 2002) |
| "Most neoplasms are dependent on glucose as their primary fuel, and their ambient glucose levels tend to be rather low owing to wasteful aerobic glycolysis and poor perfusion." | 1.31 | Prospects for glycerol-rescued hypoglycemia as a cancer therapy. ( McCarty, MF, 2001) |
| " Clinically relevant peripheral neurotoxicity tended to occur at around 1500 mg/m2 cumulative dosage at weekly doses > or =110 mg/m2." | 1.31 | Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. ( Briasoulis, E; Haidou, C; Karavasilis, V; Pavlidis, N; Piperidou, C; Tzamakou, E, 2002) |
| "Fifteen adult patients with cancer pain received 0." | 1.28 | [Epidural administration of bupivacaine in glycerine solution can prolong analgesia]. ( King, HK; Wooten, DJ; Xiao, CS, 1992) |
| "Eight malnourished cancer and 10 non-cancer patients (11% weight loss) were compared to seven well-nourished and weight-stable patients." | 1.28 | Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. ( Drott, C; Lundholm, K; Persson, H, 1989) |
| "Compared with control patients, cancer patients had a higher excretion of cortisol, adrenaline, and noradrenaline, although noradrenaline excretion reached statistical significance only when normalized to creatinine excretion." | 1.27 | Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients. ( Drott, C; Lundholm, K; Svaninger, G, 1988) |
| "While malnutrition attending cancer cachexia may be associated with variable losses of body fat, lipid metabolism has been only minimally studied." | 1.27 | Cancer cachexia and the rate of whole body lipolysis in man. ( Brennan, MF; Horowitz, GD; Jeevanandam, M; Lowry, SF, 1986) |
| "The turnover rate of glucose in the cancer patients correlated inversely to their body weight index." | 1.26 | Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients. ( Edström, S; Ekman, L; Karlberg, I; Lundholm, K; Scherstén, T, 1982) |
| "The finding that 2 uterine cancers contained 70 S RNA and reverse transcriptase indicates that uterine cancers may belong to the list of malignancies where the involvement of oncornaviruses is suspected." | 1.26 | Oncornaviruslike particles in human malignancies. ( Dörfler, W; Laufs, R; Steinke, H, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (29.17) | 18.7374 |
| 1990's | 11 (9.17) | 18.2507 |
| 2000's | 19 (15.83) | 29.6817 |
| 2010's | 41 (34.17) | 24.3611 |
| 2020's | 14 (11.67) | 2.80 |
| Authors | Studies |
|---|---|
| Umezawa, F | 1 |
| Natsume, M | 1 |
| Fukusada, S | 1 |
| Nakajima, K | 1 |
| Yamasaki, F | 1 |
| Kawashima, H | 1 |
| Kuo, CW | 1 |
| Khoo, KH | 1 |
| Shimura, T | 1 |
| Yagi, H | 1 |
| Kato, K | 1 |
| Wang, R | 3 |
| Wang, X | 5 |
| Zhao, J | 1 |
| Jin, J | 1 |
| Fan, W | 1 |
| Zhu, X | 2 |
| Chen, Q | 2 |
| Zhang, B | 2 |
| Lan, L | 1 |
| Qu, K | 1 |
| Zhu, L | 2 |
| Wang, J | 8 |
| Komatsu, N | 5 |
| Sun, S | 2 |
| Wang, Z | 3 |
| Yao, F | 1 |
| Sun, K | 1 |
| Li, Z | 3 |
| Li, C | 3 |
| Nishikawa, M | 2 |
| Yu, J | 2 |
| Kang, HG | 2 |
| Suzuki, M | 1 |
| Simón, M | 2 |
| Norregaard, K | 1 |
| Jørgensen, JT | 1 |
| Oddershede, LB | 1 |
| Kjaer, A | 1 |
| Pant, K | 1 |
| Neuber, C | 1 |
| Zarschler, K | 1 |
| Wodtke, J | 1 |
| Meister, S | 1 |
| Haag, R | 5 |
| Pietzsch, J | 1 |
| Stephan, H | 1 |
| Nagel, G | 1 |
| Sousa-Herves, A | 1 |
| Wedepohl, S | 1 |
| Calderón, M | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Huang, L | 3 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 4 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 3 |
| Wang, B | 4 |
| Zhang, Q | 5 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 3 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 3 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 5 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 7 |
| Xu, N | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 4 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 3 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 7 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 8 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 8 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 9 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 4 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 3 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 4 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 3 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 3 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 7 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 2 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 2 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 5 |
| Huang, Y | 3 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 2 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 2 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 2 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 2 |
| Luo, M | 1 |
| Wu, J | 2 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 2 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 2 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 2 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Mbous, YP | 1 |
| Hayyan, M | 1 |
| Wong, WF | 1 |
| Hayyan, A | 1 |
| Looi, CY | 1 |
| Hashim, MA | 1 |
| Rahman, M | 1 |
| Alrobaian, M | 1 |
| Almalki, WH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqarni, AO | 1 |
| Alqahtani, YS | 1 |
| Alharbi, KS | 1 |
| Alghamdi, S | 1 |
| Panda, SK | 1 |
| Fransis, A | 1 |
| Hafeez, A | 1 |
| Beg, S | 1 |
| Cherri, M | 1 |
| Ferraro, M | 1 |
| Mohammadifar, E | 1 |
| Quaas, E | 1 |
| Achazi, K | 2 |
| Ludwig, K | 1 |
| Grötzinger, C | 1 |
| Schirner, M | 1 |
| Zou, Y | 2 |
| Cheng, G | 1 |
| Xu, S | 1 |
| Zhong, Y | 1 |
| Nie, C | 1 |
| Pan, Y | 2 |
| Adeli, M | 1 |
| Xing, J | 1 |
| Zhou, S | 1 |
| Parshad, B | 1 |
| Schwerdtle, T | 1 |
| Wu, A | 1 |
| El Nemr, S | 1 |
| Al-Najjar, BY | 1 |
| Omer, HK | 1 |
| Elhissi, AMA | 1 |
| Alhnan, MA | 1 |
| Chowdhury, MR | 1 |
| Moshikur, RM | 1 |
| Wakabayashi, R | 1 |
| Tahara, Y | 1 |
| Kamiya, N | 1 |
| Moniruzzaman, M | 1 |
| Goto, M | 1 |
| Aikman, B | 1 |
| de Almeida, A | 1 |
| Meier-Menches, SM | 1 |
| Casini, A | 1 |
| Leithner, K | 1 |
| Triebl, A | 1 |
| Trötzmüller, M | 1 |
| Hinteregger, B | 1 |
| Leko, P | 1 |
| Wieser, BI | 1 |
| Grasmann, G | 1 |
| Bertsch, AL | 1 |
| Züllig, T | 1 |
| Stacher, E | 1 |
| Valli, A | 1 |
| Prassl, R | 1 |
| Olschewski, A | 1 |
| Harris, AL | 1 |
| Köfeler, HC | 1 |
| Olschewski, H | 1 |
| Hrzenjak, A | 1 |
| Kirk, TB | 2 |
| Ma, D | 2 |
| Xue, W | 2 |
| Ezrahi, S | 1 |
| Aserin, A | 1 |
| Garti, N | 1 |
| Wen, Y | 1 |
| Xu, M | 1 |
| Sang, H | 1 |
| Lin, X | 1 |
| Hong, Y | 1 |
| Feng, Y | 1 |
| Shen, L | 1 |
| Yoshino, F | 1 |
| Amano, T | 1 |
| Kimura, F | 1 |
| Furusho, Y | 1 |
| Chano, T | 1 |
| Murakami, T | 1 |
| Lee, CH | 1 |
| Rajendran, R | 1 |
| Jeong, MS | 1 |
| Ko, HY | 1 |
| Joo, JY | 1 |
| Cho, S | 1 |
| Chang, YW | 1 |
| Kim, S | 1 |
| Elmeshad, AN | 1 |
| Mortazavi, SM | 1 |
| Mozafari, MR | 1 |
| Saito, Y | 1 |
| Furukawa, T | 1 |
| Obata, T | 1 |
| Saga, T | 1 |
| Oh, SJ | 1 |
| Kim, SH | 2 |
| Jeong, K | 1 |
| Park, Y | 1 |
| Huh, YM | 1 |
| Son, JH | 1 |
| Suh, JS | 1 |
| Mokhtarani, M | 1 |
| Diaz, GA | 1 |
| Rhead, W | 1 |
| Berry, SA | 1 |
| Lichter-Konecki, U | 1 |
| Feigenbaum, A | 1 |
| Schulze, A | 1 |
| Longo, N | 1 |
| Bartley, J | 1 |
| Berquist, W | 1 |
| Gallagher, R | 1 |
| Smith, W | 1 |
| McCandless, SE | 1 |
| Harding, C | 1 |
| Rockey, DC | 1 |
| Vierling, JM | 1 |
| Mantry, P | 1 |
| Ghabril, M | 1 |
| Brown, RS | 1 |
| Dickinson, K | 1 |
| Moors, T | 1 |
| Norris, C | 1 |
| Coakley, D | 1 |
| Milikien, DA | 1 |
| Nagamani, SC | 1 |
| Lemons, C | 1 |
| Lee, B | 1 |
| Scharschmidt, BF | 1 |
| Xu, YH | 1 |
| Akasaka, T | 1 |
| Abe, S | 1 |
| Watari, F | 1 |
| Lin, JX | 1 |
| Fan, ZY | 1 |
| Lin, Q | 1 |
| Wu, DH | 1 |
| Wu, XY | 1 |
| Chen, YR | 1 |
| Fang, HY | 1 |
| Wu, DB | 1 |
| Wen, JY | 1 |
| Dong, M | 1 |
| Ma, XK | 1 |
| Wan, XB | 1 |
| Kong, M | 1 |
| Hou, L | 1 |
| Feng, C | 1 |
| Cheng, X | 1 |
| Misri, R | 2 |
| Wong, NK | 1 |
| Shenoi, RA | 1 |
| Lum, CM | 1 |
| Chafeeva, I | 1 |
| Toth, K | 1 |
| Rustum, Y | 1 |
| Kizhakkedathu, JN | 1 |
| Khan, MK | 1 |
| Jia, HZ | 1 |
| Wang, XL | 1 |
| Yang, B | 2 |
| Chen, WH | 1 |
| Chen, G | 1 |
| Zhao, YF | 1 |
| Zhuo, RX | 1 |
| Zhang, XZ | 1 |
| Ebadi, M | 1 |
| Mazurak, VC | 1 |
| Zheng, Q | 1 |
| Wu, JP | 1 |
| Jia, Y | 1 |
| Wei, Q | 1 |
| Chu, Z | 1 |
| Chen, JS | 1 |
| Liau, CT | 1 |
| Wang, HM | 1 |
| Lin, YC | 1 |
| Yang, MH | 1 |
| Chen, PM | 1 |
| Gardner, ER | 1 |
| Figg, WD | 1 |
| Sparreboom, A | 5 |
| Cho, WS | 1 |
| Han, BS | 1 |
| Nam, KT | 1 |
| Park, K | 1 |
| Jeong, J | 1 |
| Jang, DD | 2 |
| Danhier, F | 1 |
| Lecouturier, N | 1 |
| Vroman, B | 1 |
| Jérôme, C | 1 |
| Marchand-Brynaert, J | 1 |
| Feron, O | 1 |
| Préat, V | 1 |
| Han, M | 1 |
| He, CX | 1 |
| Fang, QL | 1 |
| Yang, XC | 1 |
| Diao, YY | 1 |
| Xu, DH | 1 |
| He, QJ | 1 |
| Hu, YZ | 1 |
| Liang, WQ | 1 |
| Gao, JQ | 1 |
| Hwang, M | 1 |
| Yoon, E | 1 |
| Kim, J | 1 |
| Yoo, TM | 1 |
| Koyyalagunta, D | 1 |
| Burton, AW | 1 |
| Liu, F | 1 |
| Park, JY | 1 |
| Conwell, C | 1 |
| Bathula, SR | 1 |
| Deniau, AL | 1 |
| Mosset, P | 1 |
| Pédrono, F | 1 |
| Mitre, R | 1 |
| Le Bot, D | 1 |
| Legrand, AB | 1 |
| Iannitti, T | 1 |
| Palmieri, B | 1 |
| AYRE, JE | 1 |
| DAKIN, E | 1 |
| Das, SK | 1 |
| Eder, S | 1 |
| Schauer, S | 1 |
| Diwoky, C | 1 |
| Temmel, H | 1 |
| Guertl, B | 1 |
| Gorkiewicz, G | 1 |
| Tamilarasan, KP | 1 |
| Kumari, P | 1 |
| Trauner, M | 1 |
| Zimmermann, R | 1 |
| Vesely, P | 1 |
| Haemmerle, G | 1 |
| Zechner, R | 1 |
| Hoefler, G | 1 |
| Rydén, M | 1 |
| Agustsson, T | 1 |
| Andersson, J | 1 |
| Bolinder, J | 1 |
| Toft, E | 1 |
| Arner, P | 1 |
| Sheihet, L | 1 |
| Garbuzenko, OB | 1 |
| Bushman, J | 1 |
| Gounder, MK | 1 |
| Minko, T | 1 |
| Kohn, J | 1 |
| Saatchi, K | 1 |
| Soema, P | 1 |
| Gelder, N | 1 |
| McPhee, K | 1 |
| Baker, JH | 1 |
| Reinsberg, SA | 1 |
| Brooks, DE | 1 |
| Häfeli, UO | 1 |
| Wang, S | 1 |
| Scott, H | 1 |
| García-Díaz, M | 1 |
| Kawakubo, M | 1 |
| Mroz, P | 1 |
| Sagristà, ML | 1 |
| Mora, M | 1 |
| Nonell, S | 1 |
| Hamblin, MR | 2 |
| Huang, YY | 1 |
| Balasubramanian, T | 1 |
| Yang, E | 1 |
| Luo, D | 1 |
| Diers, JR | 1 |
| Bocian, DF | 1 |
| Lindsey, JS | 1 |
| Holten, D | 1 |
| Li, M | 1 |
| Neoh, KG | 1 |
| Zong, BY | 1 |
| Tan, JY | 1 |
| Kang, ET | 1 |
| Hayashi, S | 1 |
| Inoue, D | 1 |
| Sakuyama, T | 1 |
| Tanifuji, Y | 1 |
| Moriya, K | 1 |
| Kawakubo, T | 1 |
| Verkman, AS | 1 |
| van den Bongard, HJ | 1 |
| Mathôt, RA | 1 |
| van Tellingen, O | 2 |
| Schellens, JH | 2 |
| Beijnen, JH | 2 |
| Titov, VN | 1 |
| Lisitsyn, DM | 1 |
| Burns, J | 1 |
| Stephens, M | 1 |
| GRAHAM, OL | 2 |
| KIT, S | 2 |
| WOOD, HG | 1 |
| JOFFE, S | 1 |
| GILLESPIE, R | 1 |
| HANSEN, RG | 1 |
| HARDENBROOK, H | 1 |
| WOERNLEY, DL | 1 |
| CARRUTHERS, C | 1 |
| LILGA, KT | 1 |
| BAUMLER, A | 1 |
| STIRPE, M | 1 |
| BUCCI, MG | 1 |
| FALUDI, B | 1 |
| D ANIEL, AF | 1 |
| GYURJAN, I | 1 |
| ANDA, S | 1 |
| BRUECKNER, L | 1 |
| WOOLFREY, BF | 1 |
| MAHER, RM | 1 |
| PAPO, I | 1 |
| SMITH, MC | 1 |
| LYCETTE, RM | 1 |
| LESLIE, RB | 1 |
| MARKUS, B | 2 |
| Loi, S | 1 |
| Rischin, D | 2 |
| Michael, M | 1 |
| Yuen, K | 1 |
| Stokes, KH | 2 |
| Ellis, AG | 1 |
| Millward, MJ | 2 |
| Webster, LK | 2 |
| Ishiguro, K | 1 |
| Shyam, K | 1 |
| Penketh, PG | 1 |
| Sartorelli, AC | 1 |
| Zahr, AS | 1 |
| Pishko, MV | 1 |
| Perrault, R | 1 |
| Jackson, JR | 1 |
| Martin-Villar, J | 1 |
| Smiley, RK | 1 |
| Bennegård, K | 1 |
| Edén, E | 1 |
| Ekman, L | 2 |
| Scherstén, T | 2 |
| Lundholm, K | 4 |
| Allen, ED | 1 |
| Gau, TC | 1 |
| Natale, RB | 1 |
| Edström, S | 1 |
| Karlberg, I | 1 |
| Nygren, P | 1 |
| Csoka, K | 1 |
| Jonsson, B | 1 |
| Fridborg, H | 1 |
| Bergh, J | 1 |
| Hagberg, H | 1 |
| Glimelius, B | 1 |
| Brodin, O | 1 |
| Tholander, B | 1 |
| Kreuger, A | 1 |
| Hyytinen, E | 1 |
| Visakorpi, T | 1 |
| Kallioniemi, A | 1 |
| Kallioniemi, OP | 1 |
| Isola, JJ | 1 |
| King, H | 1 |
| Xiao, CS | 2 |
| Wooten, DJ | 2 |
| Giercksky, KE | 1 |
| Watanabe, N | 1 |
| Sato, Y | 1 |
| Yamauchi, N | 1 |
| Niitsu, Y | 1 |
| Newton, H | 1 |
| Fisher, J | 1 |
| Arnold, JR | 1 |
| Pegg, DE | 1 |
| Faddy, MJ | 1 |
| Gosden, RG | 1 |
| Lokich, J | 1 |
| Anderson, N | 1 |
| Verweij, J | 4 |
| van der Burg, ME | 1 |
| Loos, WJ | 2 |
| Brouwer, E | 2 |
| Viganò, L | 2 |
| Locatelli, A | 2 |
| de Vos, AI | 1 |
| Nooter, K | 1 |
| Stoter, G | 1 |
| Gianni, L | 3 |
| Toner, GC | 1 |
| Bishop, JF | 1 |
| Olver, IN | 1 |
| Linahan, BM | 1 |
| Linsenmeyer, ME | 1 |
| Woodcock, DM | 1 |
| van Zuylen, L | 2 |
| Mross, K | 2 |
| McCarty, MF | 1 |
| Grasselli, G | 1 |
| Kirita, T | 1 |
| Ohnishi, K | 1 |
| Ohnishi, T | 1 |
| Malingré, MM | 1 |
| Ouwehand, M | 1 |
| Bardelmeijer, HA | 1 |
| Rosing, H | 1 |
| Koopman, FJ | 1 |
| Schot, ME | 1 |
| Ten Bokkel Huinink, WW | 1 |
| Gelderblom, H | 1 |
| ten Tije, AJ | 1 |
| Behringer, D | 1 |
| Mielke, S | 1 |
| van Zomeren, DM | 1 |
| Briasoulis, E | 1 |
| Karavasilis, V | 1 |
| Tzamakou, E | 1 |
| Haidou, C | 1 |
| Piperidou, C | 1 |
| Pavlidis, N | 1 |
| Steinke, H | 1 |
| Laufs, R | 1 |
| Dörfler, W | 1 |
| Brechner, VL | 1 |
| Ferrer-Brechner, T | 1 |
| Allen, GD | 1 |
| Snyder, F | 2 |
| Snyder, C | 1 |
| King, HK | 1 |
| Yang, XX | 1 |
| Drott, C | 2 |
| Persson, H | 1 |
| Svaninger, G | 1 |
| Levinson, MR | 1 |
| Groeger, JS | 1 |
| Jeevanandam, M | 3 |
| Brennan, MF | 3 |
| Legaspi, A | 1 |
| Starnes, HF | 1 |
| Beliaev, DG | 1 |
| Frid, IA | 1 |
| Genin, IB | 1 |
| Horowitz, GD | 1 |
| Lowry, SF | 1 |
| Mannheimer, E | 1 |
| Pavlova, ZV | 1 |
| Sviridova, SP | 1 |
| Isakova, ME | 1 |
| Evans, RJ | 1 |
| Mackay, IM | 1 |
| Atkinson, JN | 1 |
| Galton, DJ | 1 |
| Gilbert, C | 1 |
| Stovner, J | 1 |
| Endresen, R | 1 |
| Byfield, JE | 1 |
| Stein, JJ | 1 |
| Wood, R | 1 |
| Wenzel, M | 1 |
| Gibney, E | 1 |
| Fushing, H | 1 |
| Vanderwaal, K | 1 |
| McCowan, B | 1 |
| Koehl, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension[NCT00947544] | Phase 2 | 17 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy[NCT00999167] | Phase 2 | 189 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)[NCT00992459] | Phase 3 | 46 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)[NCT00947297] | Phase 3 | 60 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)[NCT01347073] | Phase 3 | 23 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders[NCT00551200] | Phase 2 | 14 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Clinical Study to Evaluate the Effectiveness and Safety of the Consumption of a Food Supplement in a Group of Healthy People[NCT03492086] | 60 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| Biochemical and Functional Biomarkers of Cachexia in Cancer Patients[NCT03191955] | 120 participants (Anticipated) | Observational | 2015-11-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | µmol/L (Mean) |
|---|---|
| HPN-100 | 28.68 |
| NaPBA | 37.75 |
To evaluate control of blood ammonia by HPN-100 compared with NaPBA in pediatric patients with UCDs. (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | μmol∙h/L (Mean) |
|---|---|
| HPN-100 | 603.83 |
| NaPBA | 814.62 |
blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | μmol/L (Mean) |
|---|---|
| HPN-100 | 47.77 |
| NaPBA | 55.66 |
blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | μg•h/mL AUC 0-24 (Mean) |
|---|---|
| HPN-100 | 964 |
| NaPBA | 773 |
blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | μg*h/mL AUC 0-24 (Mean) |
|---|---|
| HPN-100 | 1378 |
| NaPBA | 1015 |
blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | µg*h/ml AUC 0-24 (Mean) |
|---|---|
| HPN-100 | 631 |
| NaPBA | 236 |
"change from baseline to Month 12.~The SF 15 questionnaire consists of 15 questions that assess the following:~Physical functioning (5 questions)~Emotional functioning (4 questions)~Social functioning (3 questions)~School functioning (3 questions) Items were scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or a 3-point scale (0 [not at all], 2 [sometimes], or 4 [a lot] for the young child self-report). Items were reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score was 0-100 scale (averaged from each functional areas). In the 0-100 scale, 0 is the worst score and 100 is best score.~Improved quality of life was shown by increased total score from baseline to Month 12." (NCT00947544)
Timeframe: 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| HPN-100 | 4.0 |
blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | percentage of sample (Number) |
|---|---|
| HPN-100 | 18.4 |
| NaPBA | 31.6 |
To evaluate the safety and PK characteristics of HPN-100 compared with sodium phenylbutyrate (NaPBA) in pediatric patients with urea cycle disorders (UCDs) (NCT00947544)
Timeframe: 1 week on each treatment for a total of 2 week.
| Intervention | participants (Number) |
|---|---|
| HPN-100 | 4 |
| NaPBA | 2 |
Urinary PAGN (phenylacetylglutamine) 24-hour excretion. Urine was collect during 0-12 hrs and 12-24 hrs. (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)
| Intervention | μg (Mean) |
|---|---|
| HPN-100 | 12501037 |
| NaPBA | 12512426 |
"Number of Subjects with at Least One Hyperammonemic Crisis.~Hyperammonemic crisis is defined as follows:~• Clinical symptoms associated with ammonia of ≥ 100 µmol/L" (NCT00947544)
Timeframe: 1 year
| Intervention | participants (Number) | |
|---|---|---|
| Number of subjects with at least 1 HAC | Number of Crises | |
| Pre-Enrollment (NaPBA) | 5 | 8 |
| Safety Extension (HPN-100) | 3 | 3 |
"An HE event was defined as occurrences of either a West Haven (WH) Grade ≥2 or a WH Grade 1 and asterixis grade increase of 1 (if baseline WH = 0).~The WH criteria are widely used for rating the severity of HE and are summarized below:~Grade 1: trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance of addition Grade 2: lethargy or apathy, minimal disorientation for time or place, subtle personality change, inappropriate behavior, impaired performance of subtraction Grade 3: somnolence to semi-stupor but responsive to verbal stimuli, confusion, gross disorientation Grade 4: coma (unresponsive to verbal or noxious stimuli)~Asterixis was assessed after arm and forearm extension along with wrist dorsiflexion for 30 seconds and assigned a grade according to the following criteria:~Grade 1: rare flaps Grade 2: occasional irregular flaps Grade 3: frequent flaps Grade 4: continuous flaps" (NCT00999167)
Timeframe: Part B: 112 Days
| Intervention | participants (Number) |
|---|---|
| HPN-100 | 19 |
| Placebo | 32 |
Secondary efficacy endpoint. The time to the first HE episode during the treatment period was calculated using the Kaplan-Meier method. Subjects who did not experience an HE episode were censored at the time of their last asterixis assessment. Subjects who had no post-randomization data for the primary endpoint were considered to have an HE episode at Day 1. (NCT00999167)
Timeframe: 112 Days
| Intervention | Days (Median) |
|---|---|
| HPN-100 | NA |
| Placebo | NA |
Secondary efficacy endpoint. The total number of HE events during the treatment phase for subjects in the placebo and active arms. (NCT00999167)
Timeframe: 112 Days
| Intervention | HE event (Number) |
|---|---|
| HPN-100 | 35 |
| Placebo | 57 |
Changes from Baseline to Day 56 and the Final Visit were compared between treatment groups using an ANCOVA model for the total index RBANS score ). The index score is a sum of the scores for each of the 5 individual domains (immediate memory, visuospatial/constructional, language, attention). The minimum and maximum total index scores are 40 and 160, respectively; a higher score is better. (NCT00999167)
Timeframe: Day 56, Final Visit (D112)
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Change from Baseline to D56 (Total Score) | Change from Baseline to Final Visit (Total Score) | |
| HPN-100 | -0.5 | -10.7 |
| Placebo | 3.2 | -9.7 |
Part A: The rate of AEs and tolerability of 6 mL and 9 mL doses of HPN-100 were considered the primary safety endpoints for Part A. Safety assessments included adverse events, laboratory tests (including ammonia, hematology, coagulation, liver function and serum chemistry parameters), vital signs, physical and neurological examinations, and electrocardiograms. (NCT00999167)
Timeframe: Part A: 28 days
| Intervention | Subjects (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any AE | Gastrointestinal disorders | Metabolism and nutrition disorders | Infection and infestations | Nervous system disorders | Blood and lymphatic system disorders | Injury, poisoning and procedural complications | Musculoskeletal and connective tissue disorders | Psychiatric disorders | Any SAE | Death | |
| HPN-100 BID | 11 | 9 | 7 | 4 | 4 | 2 | 2 | 2 | 2 | 5 | 2 |
Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28
| Intervention | μg/mL (Mean) |
|---|---|
| NaPBA | 52.2 |
| HPN-100 | 38.5 |
Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28
| Intervention | μg/mL (Mean) |
|---|---|
| NaPBA | 80.9 |
| HPN-100 | 51.9 |
Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28
| Intervention | μg/mL (Mean) |
|---|---|
| NaPBA | 78.6 |
| HPN-100 | 86.8 |
The correlation between 24-hour urinary phenylacetylglutamine (PAGN) excretion (U-PAGN24-hour Excr) and venous ammonia AUC0-24 was summarized and the correlation was tested using the Spearman rank-order correlation. (NCT00992459)
Timeframe: 28 Days
| Intervention | correlation coefficient (Number) |
|---|---|
| NaPBA | 0.437 |
| HPN-100 | 0.219 |
Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28
| Intervention | µmol/L (Mean) |
|---|---|
| NaPBA | 70.83 |
| HPN-100 | 60.94 |
Severity of symptomatic hyperammonemic crises was measured by peak ammonia level (µmol/L) when it is >= 100 µmol/L. (NCT00992459)
Timeframe: 29 Days
| Intervention | events (Number) |
|---|---|
| NaPBA | 1 |
| HPN-100 | 0 |
NaPBA treated arm: total 345 blood samples were collected. HPN-100 treated arm: 343 blood samples were collected. (NCT00992459)
Timeframe: on Day 14 and Day 28
| Intervention | samples (Number) |
|---|---|
| NaPBA | 125 |
| HPN-100 | 122 |
(NCT00992459)
Timeframe: 29 Days
| Intervention | participants (Number) |
|---|---|
| NaPBA | 23 |
| HPN-100 | 27 |
Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. Arm A day 14 and Arm B day 28 data were combined as a NaPBA treatment Arm. Arm B day 14 and Arm A day 28 data were combined as a HPN-100 treatment Arm. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28
| Intervention | μmol∙h/L (Mean) |
|---|---|
| NaPBA | 976.6 |
| HPN-100 | 865.35 |
(NCT00992459)
Timeframe: 24 hours on Day 14 of each treatments
| Intervention | μg (Mean) |
|---|---|
| NaPBA | 13627515 |
| HPN-100 | 13502745 |
Number of hyperammonemic crises per patient (NCT00947297)
Timeframe: 1 year
| Intervention | hyperammonemic events (Mean) |
|---|---|
| HPN-100 | 0.20 |
Drug preference will be noted at week 3 (NCT00947297)
Timeframe: Month 1 post dose
| Intervention | % preferred HPN-100 (Number) |
|---|---|
| HPN-100 | 90 |
(NCT00947297)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| HPN-100 | 33 |
Venous Ammonia levels over time (NCT00947297)
Timeframe: 1 Year
| Intervention | Umol/L (Mean) | |
|---|---|---|
| Baseline | Month 12 | |
| HPN-100 | 27.623 | 24.202 |
Rate of adverse events during the Safety Extension portion of the protocol ( please note: HPN-100 treatment only during Safety Extension ) (NCT01347073)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| HPN-100 | 23 |
Rate of adverse events during the Switch-Over portion of the Protocol (NCT01347073)
Timeframe: 2 weeks
| Intervention | participants (Number) |
|---|---|
| NaPBA | 0 |
| HPN-100 | 6 |
24-hour ammonia AUC of blood ammonia levels on Days 1 (NaPBA) and 10 (HPN-100) were compared. Ammonia was assessed at Hour 0 (pre-first dose, fasted), Hour 8 (~2-4 hours after lunch or the second main meal and dose of NaPBA), Hour 12 (~4 hours after the last main meal) and 24 hours post-first dose (pre-first dose on following day, fasted). (NCT01347073)
Timeframe: 2 weeks
| Intervention | umol/L*hours (Mean) |
|---|---|
| NaPBA | 914.43 |
| HPN-100 | 647.63 |
Ammonia values were converted to SI units (umol/L) and normalized to a standard ULN of 35 umol/L prior to analysis (NCT01347073)
Timeframe: 2 weeks
| Intervention | Ammonia Values > ULN (Number) |
|---|---|
| NaPBA | 22 |
| HPN-100 | 8 |
Rate of HAC during pre-enrollment on NaPBA compared to HAC during HPN-100 treatment (NCT01347073)
Timeframe: 1 year
| Intervention | number of crises (Number) |
|---|---|
| Pre-enrollment | 29 |
| Long-term Phase | 12 |
(NCT00551200)
Timeframe: during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|---|
| Buphenyl | 7 |
| HPN-100 | 5 |
(NCT00551200)
Timeframe: during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|---|
| Buphenyl | 1 |
| HPN-100 | 0 |
(NCT00551200)
Timeframe: End of Study
| Intervention | participants (Number) | |
|---|---|---|
| prefer Buphenyl | prefer HPN-100 | |
| Buphenyl to HPN-100 | 1 | 9 |
measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)
| Intervention | μg*h/mL (Mean) | ||
|---|---|---|---|
| AUC0-24 PBA (phenylbutyrate) in plasma | AUC0-24 PAA (phenylacetate) in plasma | AUC0-24 PAGN (phenylacetylglutamine) in plasma | |
| HPN-100 Steady State | 540 | 575 | 1098 |
| NaPBA Steady State | 740 | 596 | 1133 |
Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation
| Intervention | μmol/L (Mean) | |
|---|---|---|
| in peak | in TNAUC (time-normalized area under the curve) | |
| HPN-100 Steady State | 56.3 | 26.5 |
| NaPBA Steady State | 79.1 | 38.4 |
16 reviews available for glycerol and Neoplasms
| Article | Year |
|---|---|
Clinical value and molecular mechanism of AQGPs in different tumors.
Topics: Aquaglyceroporins; Glycerol; Humans; Hydrogen Peroxide; Neoplasms | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Superbranched polyglycerol nanostructures as drug delivery and theranostics tools for cancer treatment.
Topics: Biocompatible Materials; Drug Carriers; Drug Delivery Systems; Glycerol; Humans; Nanostructures; Neo | 2021 |
Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents.
Topics: Animals; Antineoplastic Agents; Aquaporins; Glycerol; Humans; Hydrogen Peroxide; Models, Biological; | 2018 |
Basic principles of drug delivery systems - the case of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Biological Transport; Drug Delivery Syst | 2019 |
Potential of Fatty Oils from Traditional Chinese Medicine in Cancer Therapy: A Review for Phytochemical, Pharmacological and Clinical Studies.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Drugs, Chinese Herbal; Fatty Acids; Glycerol; Humans; | 2019 |
Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia.
Topics: Adipokines; Adipose Tissue; Biomarkers; Cachexia; Carrier Proteins; Cytokines; Glycerol; Glycoprotei | 2015 |
The role of chemical neurolysis in cancer pain.
Topics: Animals; Ethanol; Glycerol; Humans; Neoplasms; Nerve Block; Pain; Pain Management; Phenol | 2010 |
Multiple beneficial health effects of natural alkylglycerols from shark liver oil.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Fish Oils; Glycerol; Humans; Mice; | 2010 |
An update on the therapeutic role of alkylglycerols.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Clinical Trials as Topic; Fish Oils; Glycerol; | 2010 |
Palliative wound management: the use of a glycerine hydrogel.
Topics: Adult; Aged; Cryoprotective Agents; Female; Glycerol; Humans; Hydrogels; Male; Neoplasms; Palliative | 2003 |
Role of formulation vehicles in taxane pharmacology.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP | 2001 |
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Pharmaceutical; Cisplatin; Docet | 2001 |
A new strategy for cancer therapy based on a predictive indicator.
Topics: Apoptosis; Forecasting; Genes, p53; Genetic Therapy; Genotype; Glycerol; Humans; Molecular Chaperone | 2001 |
Glycerolipids and cancer.
Topics: Animals; Choline; Chromatography, Thin Layer; Dogs; Ethanolamines; Ethers; Glycerides; Glycerol; Hum | 1975 |
10 trials available for glycerol and Neoplasms
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
A comparison of dioctahedral smectite and iodine glycerin cream with topical mouth rinse in treatment of chemotherapy induced oral mucositis: a pilot study.
Topics: Administration, Topical; Adult; Aged; Anti-Infective Agents, Local; Antineoplastic Agents; Female; G | 2015 |
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological A | 2008 |
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carboplatin; Cross-Over Stu | 2004 |
Prolongation of epidural bupivacaine analgesia with glycerin.
Topics: Aged; Analgesia, Epidural; Bupivacaine; Chronic Disease; Delayed-Action Preparations; Female; Glycer | 1993 |
Phase I trial of cremophor EL with bolus doxorubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Cross-Over Studies; Doxorubicin; Female; Glycerol; Humans; | 1998 |
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Glycerol; Humans; Infusions, Intravenous; Neoplasms; Paclitaxel; | 2000 |
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Drug Combin | 2001 |
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Drug Administration Schedule; Fema | 2002 |
96 other studies available for glycerol and Neoplasms
| Article | Year |
|---|---|
Cancer Malignancy Is Correlated with Upregulation of PCYT2-Mediated Glycerol Phosphate Modification of α-Dystroglycan.
Topics: Dystroglycans; Glycerol; Glycerophosphates; Humans; Neoplasms; Phosphates; Polysaccharides; RNA Nucl | 2022 |
Poly(Glycerol)-Based Biomedical Nanodevices Constructed by Functional Programming on Inorganic Nanoparticles for Cancer Nanomedicine.
Topics: Glycerol; Humans; Nanomedicine; Nanoparticles; Neoplasms; Polymers | 2023 |
Breast cancer cell-derived exosome-delivered microRNA-155 targets UBQLN1 in adipocytes and facilitates cancer cachexia-related fat loss.
Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Animals; Autophagy-Related Proteins; Cachexia; Exo | 2023 |
Rational Design, Multistep Synthesis and in Vitro Evaluation of Poly(glycerol) Functionalized Nanodiamond Conjugated with Boron-10 Cluster and Active Targeting Moiety for Boron Neutron Capture Therapy.
Topics: Animals; Boron; Boron Compounds; Boron Neutron Capture Therapy; Glycerol; Mice; Nanodiamonds; Neopla | 2023 |
Fractionated photothermal therapy in a murine tumor model: comparison with single dose.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Radiation; Female; Gl | 2019 |
Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging.
Topics: Diagnostic Techniques and Procedures; Endocytosis; ErbB Receptors; Glycerol; Hep G2 Cells; Humans; N | 2020 |
Matrix Metalloproteinase-sensitive Multistage Nanogels Promote Drug Transport in 3D Tumor Model.
Topics: Cell Survival; Delayed-Action Preparations; Dendrimers; Doxorubicin; Drug Carriers; Drug Liberation; | 2020 |
Simulation of Deep Eutectic Solvents' Interaction with Membranes of Cancer Cells Using COSMO-RS.
Topics: Choline; Ethylene Glycol; Glycerol; Hydrogen Bonding; Neoplasms; Solvents | 2020 |
Biodegradable Dendritic Polyglycerol Sulfate for the Delivery and Tumor Accumulation of Cytostatic Anticancer Drugs.
Topics: Antineoplastic Agents; Cytostatic Agents; Glycerol; Humans; Neoplasms; Polymers; Sulfates | 2021 |
Effect of Protein Corona on Mitochondrial Targeting Ability and Cytotoxicity of Triphenylphosphonium Conjugated with Polyglycerol-Functionalized Nanodiamond.
Topics: A549 Cells; Cell Proliferation; Drug Carriers; Glycerol; HeLa Cells; Humans; Mitochondria; Nanodiamo | 2021 |
Co-Delivery of Doxorubicin and Chloroquine by Polyglycerol Functionalized MoS2 Nanosheets for Efficient Multidrug-Resistant Cancer Therapy.
Topics: Chloroquine; Disulfides; Doxorubicin; Drug Resistance, Neoplasm; Glycerol; HeLa Cells; Humans; Micro | 2021 |
Retinoic Acid-Loaded Dendritic Polyglycerol-Conjugated Gold Nanostars for Targeted Photothermal Therapy in Breast Cancer Stem Cells.
Topics: Glycerol; Gold; Neoplasms; Neoplastic Stem Cells; Photothermal Therapy; Polymers; Tretinoin | 2021 |
Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Carriers; Glyc | 2018 |
Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Drug Compounding; Drug Delivery Systems; Drug Hypersensitivity; E | 2018 |
The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells.
Topics: A549 Cells; Animals; Glucose; Glutamine; Glycerol; Heterografts; Humans; Lactic Acid; Male; Mice; Mi | 2018 |
Construction of a High-Efficiency Drug and Gene Co-Delivery System for Cancer Therapy from a pH-Sensitive Supramolecular Inclusion between Oligoethylenimine- graft-β-cyclodextrin and Hyperbranched Polyglycerol Derivative.
Topics: Animals; beta-Cyclodextrins; Biocompatible Materials; Cell Movement; Doxorubicin; Drug Delivery Syst | 2018 |
Magnetofluorescent nanohybrid comprising polyglycerol grafted carbon dots and iron oxides: Colloidal synthesis and applications in cellular imaging and magnetically enhanced drug delivery.
Topics: Animals; Antineoplastic Agents; Carbon; Cell Survival; Colloids; Drug Delivery Systems; Ferric Compo | 2019 |
Preferential Tumor Accumulation of Polyglycerol Functionalized Nanodiamond Conjugated with Cyanine Dye Leading to Near-Infrared Fluorescence In Vivo Tumor Imaging.
Topics: Animals; Benzothiazoles; Carbocyanines; Fluorescence; Glycerol; Green Fluorescent Proteins; HeLa Cel | 2019 |
Bioimaging of targeting cancers using aptamer-conjugated carbon nanodots.
Topics: Animals; Carbon; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Diagnostic Imag | 2013 |
Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Cell Line, Tumor; Cholesterol; Drug Delivery Systems; Fluorourac | 2014 |
Molecular imaging of aquaglycero-aquaporins: its potential for cancer characterization.
Topics: Animals; Aquaglyceroporins; Carbon Radioisotopes; Cell Line, Tumor; Glycerol; Heterografts; Humans; | 2013 |
Measurement depth enhancement in terahertz imaging of biological tissues.
Topics: Animals; Ethanol; Glycerol; Image Enhancement; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop | 2013 |
Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gl | 2014 |
Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersomes for tumor metastasis therapy.
Topics: Administration, Cutaneous; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Glycerol; H | 2015 |
Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.
Topics: Animals; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Glycerol; HT29 Cells; Humans; Hydr | 2015 |
Polymeric assembly of hyperbranched building blocks to establish tunable nanoplatforms for lysosome acidity-responsive gene/drug co-delivery.
Topics: Boronic Acids; Doxorubicin; Drug Delivery Systems; Gene Transfer Techniques; Glycerol; Humans; Hydro | 2015 |
Star-Shaped Amphiphilic Hyperbranched Polyglycerol Conjugated with Dendritic Poly(l-lysine) for the Codelivery of Docetaxel and MMP-9 siRNA in Cancer Therapy.
Topics: Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Glycerol; Humans; MCF-7 Cells; Neoplasms; Polyly | 2016 |
Complex Assembly of Polymer Conjugated Mesoporous Silica Nanoparticles for Intracellular pH-Responsive Drug Delivery.
Topics: A549 Cells; Cross-Linking Reagents; Drug Carriers; Drug Delivery Systems; Endocytosis; Fluorescent D | 2016 |
Carcinogenicity study of 3-monochloropropane-1,2-diol in Sprague-Dawley rats.
Topics: alpha-Chlorohydrin; Animals; Body Weight; Carcinogenicity Tests; Carcinogens; Female; Glycerol; Male | 2008 |
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Drug Carriers; Drug Evaluation | 2009 |
A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Prolife | 2009 |
Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology.
Topics: alpha-Chlorohydrin; Animals; Benchmarking; Carcinogens; Dose-Response Relationship, Drug; Female; Fo | 2009 |
Targeted cancer therapy with novel high drug-loading nanocrystals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; C | 2010 |
Cervical cytology tests in cancer diagnosis; glycerine technique for mailing.
Topics: Female; Glycerol; Humans; Neoplasms; Uterine Neoplasms; Vaginal Smears | 1946 |
Adipose triglyceride lipase contributes to cancer-associated cachexia.
Topics: Adipose Tissue, White; Animals; Blood Glucose; Body Mass Index; Body Weight; Cachexia; Cytokines; Fa | 2011 |
Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states.
Topics: Adipocytes; Adipose Tissue, White; Adult; Aged; Biomarkers; Biomarkers, Tumor; Body Mass Index; Cach | 2012 |
Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Female; Glycerol; Human | 2012 |
Hyperbranched polyglycerols as trimodal imaging agents: design, biocompatibility, and tumor uptake.
Topics: Biocompatible Materials; Cells, Cultured; Complement Activation; Erythrocytes; Glycerol; Humans; Neo | 2012 |
Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Drug Carriers; Femal | 2012 |
Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Glycerol; Light; Liposomes; Mice; Mice, Inbred BALB C; Mic | 2012 |
Stable synthetic bacteriochlorins for photodynamic therapy: role of dicyano peripheral groups, central metal substitution (2H, Zn, Pd), and Cremophor EL delivery.
Topics: Animals; Coordination Complexes; Glycerol; HeLa Cells; Humans; Neoplasms; Palladium; Pharmaceutical | 2012 |
Methotrexate-conjugated and hyperbranched polyglycerol-grafted Fe₃O₄ magnetic nanoparticles for targeted anticancer effects.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cell Survival; Dru | 2013 |
[Usefulness of subarachnoid phenol-glycerin block therapy for enabling cancer patients with refractory anal pain to proceed to home-based care].
Topics: Aged; Anus Diseases; Female; Glycerol; Home Care Services; Humans; Male; Neoplasms; Pain, Intractabl | 2012 |
Aquaporins.
Topics: Animals; Aquaporins; Bacteria; Cell Membrane Permeability; Gene Knockout Techniques; Glycerol; Human | 2013 |
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Glycerol | 2002 |
[Esterification of fatty acids by alcohols and functional role of polar and non-polar lipids in blood flow. Double bonds of lipid fatty acids in lipoproteins].
Topics: Adolescent; Adult; Alcohols; Animals; Arteriosclerosis; Child; Cholesterol Esters; Choline; Fatty Ac | 2003 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Glycerol metabolism of normal and malignant lymphatic tissue; the preferential labeling of tumor serine and glycine.
Topics: Glycerol; Glycine; Humans; Lymphatic System; Lymphoid Tissue; Lymphoma; Lymphoma, Non-Hodgkin; Neopl | 1956 |
Lactose synthesis. IV. The synthesis of milk constituents after unilateral injection of glycerol-1,3-C14 into the pudic artery.
Topics: Arteries; Carbohydrate Metabolism; Glycerol; Lactose; Milk; Neoplasms; Sarcoma | 1958 |
Distribution of cytochrome oxidase activity in Ehrlich ascites cell particulates obtained from glycerol homogenates.
Topics: Ascites; Cytochromes; Electron Transport Complex IV; Glycerol; Neoplasms | 1959 |
[ACTION OF GLYCEROL ON EXOPHTHALMOS].
Topics: Edema; Exophthalmos; Glycerol; Humans; Hyperthyroidism; Neoplasms; Vascular Diseases | 1963 |
SUGAR ANTAGONISMS IN PLANT TUMOUR CELLS INDUCED BY 2,4-DICHLOROPHENOXYACETIC ACID.
Topics: 2,4-Dichlorophenoxyacetic Acid; Antimetabolites; Arabinose; Carbohydrates; Disaccharides; Fructose; | 1963 |
INFLUENCE OF GLYCEROL-GUAIACOL-ETHER UPON GASTRIC CHANGES AFTER X-RAY THERAPY.
Topics: Biomedical Research; Ether; Gastric Juice; Glycerol; Guaiacol; Guaifenesin; Humans; Kymography; Neop | 1963 |
RADIOAUTOGRAPHIC EVALUATION OF FREEZE-THAW BUFFERS USING NUCLEIC ACID- AND GLYCINE-RELATED SYNTHETIC SYSTEMS IN VITRO.
Topics: Adenine; Autoradiography; Buffers; Dextrans; Dimethyl Sulfoxide; Glycerol; Glycine; In Vitro Techniq | 1964 |
THE MEDICAL TREATMENT OF SPASTICITY.
Topics: Anesthesia; Anesthesia, Spinal; Breast Neoplasms; Drug Therapy; Glycerol; Humans; Injections; Inject | 1964 |
[POSSIBILITIES OF ANTALGIC THERAPY IN PAIN DUE TO GYNECOLOGIC CARCINOMAS].
Topics: Carcinoma; Cordotomy; Cresols; Female; Genital Neoplasms, Female; Glycerol; Humans; Injections; Inje | 1964 |
HISTOLOGICAL FINDINGS FOLLOWING INTRATHECAL INJECTIONS OF PHENOL SOLUTIONS FOR RELIEF OF PAIN.
Topics: Cats; Drug Therapy; Glycerol; Histology; Humans; Injections; Injections, Spinal; Meningitis; Neoplas | 1964 |
FLUORESCENCE OF MALIGNANT TISSUE.
Topics: Fluorescence; Glycerol; Histocytochemistry; Neoplasms; Pathology; Ultraviolet Rays | 1965 |
[Comparative studies of the Papanicolaou method and Hoffmann's Giemsa-glycerin drop staining in the cytodiagnosis of cancer].
Topics: Cytodiagnosis; Glycerol; Humans; Neoplasms; Staining and Labeling | 1951 |
[Comparative studies of the Papanicolaou method and Hoffmann's Giemsa-glycerin drop staining in the cytodiagnosis of cancer].
Topics: Cytodiagnosis; Glycerol; Humans; Neoplasms; Staining and Labeling | 1951 |
Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Blotting, Western; Cell Line | 2005 |
Encapsulation of paclitaxel in macromolecular nanoshells.
Topics: Cell Cycle; Cell Line, Tumor; Cytoskeleton; Drug Delivery Systems; Glycerol; Humans; Macromolecular | 2007 |
Experience with the use of frozen blood.
Topics: Adolescent; Adult; Aged; Anemia; Blood Preservation; Blood Transfusion; Female; Freezing; Glycerol; | 1967 |
Metabolic response of whole body and peripheral tissues to enteral nutrition in weight-losing cancer and noncancer patients.
Topics: Aged; Amino Acids; Body Weight; Energy Metabolism; Enteral Nutrition; Fatty Acids, Nonesterified; Fe | 1983 |
In vitro colony formation by cryopreserved primary human tumor cells.
Topics: Colony-Forming Units Assay; Cryoprotective Agents; Dimethyl Sulfoxide; Freezing; Glycerol; Humans; N | 1984 |
Glucose turnover, gluconeogenesis from glycerol, and estimation of net glucose cycling in cancer patients.
Topics: Adult; Aged; Carbon Radioisotopes; Female; Gluconeogenesis; Glucose; Glycerol; Humans; Kinetics; Mal | 1982 |
The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Drug Synergism; Fluorometry; Glycerol; Huma | 1995 |
Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization.
Topics: Breast Neoplasms; Centromere; Chromatin; Chromosomes, Human; DNA Probes; DNA, Neoplasm; Formaldehyde | 1994 |
Misdiagnosis of cancer due to multiple glove powder granulomas.
Topics: Absorption; Cross-Linking Reagents; Diagnosis, Differential; Epichlorohydrin; False Negative Reactio | 1997 |
[Gene delivery into human cancer cells via transferrin receptor].
Topics: Adenoviridae; Biotin; DNA; Drug Delivery Systems; Genetic Therapy; Genetic Vectors; Glycerol; Humans | 1998 |
Permeation of human ovarian tissue with cryoprotective agents in preparation for cryopreservation.
Topics: Adult; Antineoplastic Agents; Cryopreservation; Cryoprotective Agents; Dimethyl Sulfoxide; Ethylene | 1998 |
Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Glycerol; Humans; | 1998 |
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP | 1998 |
Prospects for glycerol-rescued hypoglycemia as a cancer therapy.
Topics: Animals; Antineoplastic Agents; Gluconeogenesis; Glycerol; Humans; Hypoglycemia; Hypoglycemic Agents | 2001 |
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Dose-Response Relationship, Drug; | 2002 |
Oncornaviruslike particles in human malignancies.
Topics: Centrifugation, Density Gradient; Female; Glycerol; Humans; Neoplasms; Oncogenic Viruses; RNA; RNA-D | 1976 |
Anesthetic measures in management of pain associated with malignancy.
Topics: Analgesia; Anesthesia, Epidural; Autonomic Nerve Block; Carcinoma; Denervation; Ethanol; Female; Gly | 1977 |
[Epidural administration of bupivacaine in glycerine solution can prolong analgesia].
Topics: Adult; Analgesia, Epidural; Bupivacaine; Female; Glycerol; Humans; Injections, Epidural; Male; Middl | 1992 |
[Neural blockage of phenol-glycerine for cancer pain].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Glycerol; Humans; Male; Middle Aged; Neoplasms; | 1991 |
Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer.
Topics: Aged; Blood Pressure; Cachexia; Energy Metabolism; Epinephrine; Fatty Acids, Nonesterified; Female; | 1989 |
Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients.
Topics: Aged; Body Composition; Catecholamines; Creatinine; Epinephrine; Female; Glycerol; Humans; Hydrocort | 1988 |
Free fatty acid turnover and lipolysis in septic mechanically ventilated cancer-bearing humans.
Topics: Adolescent; Adult; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Infectio | 1988 |
Whole body lipid and energy metabolism in the cancer patient.
Topics: Adult; Aged; Cachexia; Energy Metabolism; Esterification; Fatty Acids, Nonesterified; Female; Glycer | 1987 |
[Analgesic therapy of cancer outpatients].
Topics: Adult; Aged; Ambulatory Care; Analgesics; Drug Evaluation; Ethanol; Glycerol; Humans; Middle Aged; N | 1987 |
Cancer cachexia and the rate of whole body lipolysis in man.
Topics: Adult; Aged; Cachexia; Fatty Acids, Nonesterified; Female; Glycerol; Humans; Lipid Metabolism; Lipol | 1986 |
[Viability and effectivness of deep cooled human bone marrow cells].
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; Cell Co | 1970 |
[Chemical denervation analgesia of incurable oncological patients].
Topics: Adult; Aged; Analgesia; Anesthesia, Epidural; Ethanol; Female; Glycerol; Humans; Male; Middle Aged; | 1971 |
Subarachnoid phenol nerve blocks for relief of pain in advanced malignancy.
Topics: Adult; Aged; Autonomic Nerve Block; Colonic Neoplasms; Female; Genital Neoplasms, Female; Glycerol; | 1972 |
Regulatory defect of glycolysis in human lipoma.
Topics: Adipose Tissue; Citrates; Feedback; Glucose; Glucosephosphates; Glycerides; Glycerol; Glycolysis; Hu | 1974 |
Intrathecal phenol for cancer pain.
Topics: Fecal Incontinence; Glycerol; Headache; Humans; Injections, Spinal; Methods; Motor Neurons; Muscles; | 1972 |
A simple radiochemical assay of inhibition by chemotherapeutic agents of precursor incorporation into biopsy samples, effusions, and leukocyte preparations.
Topics: Amino Acids; Animals; Antineoplastic Agents; Biological Assay; Biopsy; Carbon Isotopes; Carcinoma, E | 1968 |
Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues.
Topics: Adolescent; Alkenes; Chromatography, Thin Layer; Ethers; Glycerol; Humans; Lipids; Male; Neoplasms | 1969 |
[HTO-formation from tritium labelled compounds in vivo as proof of tritium incorporation].
Topics: Animals; Ascites; Estradiol; Female; Glycerol; Glycosuria; Hydrocortisone; Lactates; Neoplasms; Preg | 1969 |
What to expect in 2018: science in the new year.
Topics: Astronauts; Astronomy; Climate Change; Clinical Trials as Topic; DNA, Ancient; Drug Resistance, Micr | 2018 |
Cancer, climate, plastics: why 'earthshots' are harder than moonshots.
Topics: Anti-Bacterial Agents; Biomedical Research; Cooperative Behavior; Environmental Pollution; Global Wa | 2019 |
Multi-scale clustering by building a robust and self correcting ultrametric topology on data points.
Topics: Animals; Autistic Disorder; Behavior, Animal; Cluster Analysis; Computational Biology; Gene Expressi | 2013 |